AUS
NZ
UK
CA
USA
IND
_01_22_2025_07_55_26_045637.jpg)
A glance at three favourite stocks from the biotech-pharmaceutical sector.
Mayne Pharma Group LimitedÂ
Mayne Pharma Group Limited (ASX:MYX) is a specialty pharmaceutical company based out of Salisbury South, Australia. It is engaged in manufacturing and commercialised sale of pharmaceutical products worldwide, through four business divisions comprising Metrics Contract Services, Mayne Pharma International, Specialty Brands and Generic Products.
Mayne Pharma currently has a market capitalisation of AUD 1.28 billion with ~1.58 billion outstanding shares. With the close of the last trading session on February 13th, 2019, the MYX stock was trading at a market price of AUD 0.845, up by 4.321%, indicating an intra-day gain of AUD 0.035. Around 4.83 million volume of shares were traded. Besides, the stock has generated a positive YTD return of 8.72%.
Recently, the company launched LEXETTE⢠Foam 0.055 in the United States. It is a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients. The announcement follows the previous launch of TOLSURETM 65 mg capsule earlier in January. For the FY 2018, Mayne Pharma had positive operating cash flow of AUD 122 million. Specifically, for the Specialty Brands division, the sales were USD 35 million in 2H FY2018, up 121% on 1H FY2018. Also, all the divisions posted an increase in gross profits.
Benitec Biopharma Limited
The Sydney-based Benitec Biopharma (ASX:BLT), established in 1995, is a clinical-stage biotechnology company which develops novel genetic medicines in laboratories in Hayward, California (USA), with collaborators and licensees around the world. It has a patent over DNA-directed RNA interference or ddRNAi platform, which combines RNA interference, or RNAi, and gene therapy to develop medicines that assist in silencing of disease-causing genes following a single administration for a sustained period of time.
With a market capitalisation of AUD 26.99 million, the company has ~257.03 million outstanding shares on the ASX. With the close of the last trading session on February 13th, the BLT stock was trading at a market price of AUD 0.145, up by a high 38.095%, indicating an intra-day gain of AUD 0.040. The stock has generated a YTD return of 5% so far.
For the quarter ended December 31st, 2018, the company posted cash reserves of around AUD 25 million and also received January approximately AUD 4.1 million cash refund for FY2018 under the Australian Federal Governmentâs Research & Development Tax Incentive Scheme in January 2019.
Oncosil Medical Ltd
Oncosil Medical Ltd (ASX:OSL), formerly known as NeuroDiscovery Limited, is a North Sydney-based medical device company engaged in developing localised treatments for cancer in Australia. Its flagship product is the brachytherapy device âOncoSilâ, comprising OncoSil Phosphorous-32 Microparticles and OncoSil Diluent, that implant a pre-specified dose of beta radiation emitting isotope directly into cancerous tissue for the treatment of both pancreatic and liver cancer.
The OSL stock has a market capitalisation of AUD 100.91 million and last traded at a market price of AUD 0.160 with the close of the trading session on February 13th, 2019. Around 128,666 volume of shares were traded in total. The stock has generated a negative return yield of 3.03% in the last six months and also a negative YTD return of 8.57%.
The company reported the net cash and cash equivalents at AUD 13.03 million at the end of the quarter ended December 31st, 2018, down from the previous quarterâs AUD 16.12 million. There were major cash burns from operating activities at around AUD 3.09 million and no investing or financing initiatives during the period.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
